The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Sumitomo Pharma to Offload Asian Biz to Trader Marubeni
Sumitomo Pharma said on April 1 that it is divesting its Asian business to major Japanese trading house Marubeni for roughly 72 billion yen in a deal that forms part of its post-Latuda (lurasidone) turnaround efforts. The Asian business will…
To read the full story
Related Article
BUSINESS
- Hisamitsu to Go Private in Management Buyout Valued at 400 Billion Yen
January 8, 2026
- AbbVie Introduces No-Relocation Work Option for Sales Staff
January 8, 2026
- Generic Makers Positive on New AG Pricing, Cite Gains in Productivity and Predictability
January 8, 2026
- Bayer, University of Tsukuba Hospital Tie Up for Early Heart Failure Detection
January 8, 2026
- Envudeucitinib Hits PIII Goals in Psoriasis, JNDA Planned for 2027: Kaken
January 8, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…